Outcomes after Surgery for Endocarditis among Intravenous Drug Users and Nonusers

Abstract

Background The optimal treatment strategy for intravenous drug users (IVDU) with infective endocarditis (IE) is controversial. We therefore sought to investigate outcomes among IVDUs after surgery for IE.

Methods We retrospectively reviewed all 192 consecutive patients who underwent an operation for IE between 2005 and 2016 in the Helsinki University Hospital. Forty-seven patients (24.5%) were IVDUs and 145 (75.5%) were non-IVDUs. Mortality and reinfection and reoperation rates were evaluated.

Results IVDUs were younger (29.9 vs. 63.8 years, p < 0.001) and had less cardiovascular risk factors and lower EuroSCORE II (4.3 vs. 7.3%, p < 0.001), but Staphylococcus aureus infection (66.0 vs. 23.4%, p < 0.001), tricuspid valve endocarditis (34.0 vs. 2.8%, p < 0.001), and liver disease (63.8 vs. 2.8%, p < 0.001) occurred more often in IVDUs than in non-IVDUs. Thirty-day mortality of IVDUs was 8.5% and that of non-IVDUs was 6.9% (p = 0.711). Survival of IVDUs at 5 years was 70.8 ± 7.4% and survival of non-IVDUs was 67.9 ± 4.7% (p = 0.678). Relative to an age- and sex-matched general population, IVDUs had 58.6 (95% confidence interval [CI]: 33.7–101.9; p < 0.001) and non-IVUD 4.4 (95% CI: 3.1–6.2; p < 0.001) standardized mortality ratio. IVDUs had a higher reinfection rate at 5 years (25.8 ± 7.7% vs. 3.0 ± 1.7%, p < 0.001) and a higher early reoperation rate than non-IVDUs (10.6 vs. 1.4%, p = 0.003).

Conclusions IVDUs and non-IVDUs had comparable survival at 5 years, but IVDUs had a very significantly increased risk of death in comparison to an age- and sex-matched general population. IVDUs had higher reinfection and early reoperation rates. Survival was poor after medically treated reinfection.

Keywords

endocarditis - heart valve surgery - outcomes (includes mortality and morbidity)

Publikationsverlauf

Eingereicht: 01. September 2020

Angenommen: 28. Januar 2021

Artikel online veröffentlicht:
27. Juni 2021

• References

• 1 Rudasill SE, Sanaiha Y, Mardock AL. et al. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol 2019; 73 (05) 559-570
• 2 Colville T, Sharma V, Albouaini K. Infective endocarditis in intravenous drug users: a review article. Postgrad Med J 2016; 92 (1084): 105-111
• 3 Nguemeni Tiako MJ, Mori M, Bin Mahmood SU. et al. Recidivism is the leading cause of death among intravenous drug users who underwent cardiac surgery for infective endocarditis. Semin Thorac Cardiovasc Surg 2019; 31 (01) 40-45
• 4 Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med 2007; 44 (04) 369-374
• 5 Habib G, Lancellotti P, Antunes MJ. et al; 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36 (44) 3075-3128
• 6 Kim JB, Ejiofor JI, Yammine M. et al. Surgical outcomes of infective endocarditis among intravenous drug users. J Thorac Cardiovasc Surg 2016; 152 (03) 832-841.e1
• 7 Østerdal OB, Salminen PR, Jordal S, Sjursen H, Wendelbo Ø, Haaverstad R. Cardiac surgery for infective endocarditis in patients with intravenous drug use. Interact Cardiovasc Thorac Surg 2016; 22 (05) 633-640
• 8 Ternhag A, Cederström A, Törner A, Westling K. A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden. PLoS One 2013; 8 (07) e67519
• 9 Rabkin DG, Mokadam NA, Miller DW, Goetz RR, Verrier ED, Aldea GS. Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann Thorac Surg 2012; 93 (01) 51-57
• 10 Weymann A, Borst T, Popov AF. et al. Surgical treatment of infective endocarditis in active intravenous drug users: a justified procedure?. J Cardiothorac Surg 2014; 9: 58
• 11 Perucci CA, Forastiere F, Rapiti E, Davoli M, Abeni DD. The impact of intravenous drug use on mortality of young adults in Rome, Italy. Br J Addict 1992; 87 (12) 1637-1641
• 12 Smyth B, Fan J, Hser YI. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. J Addict Dis 2006; 25 (04) 37-47
• 13 Kaiser SP, Melby SJ, Zierer A. et al. Long-term outcomes in valve replacement surgery for infective endocarditis. Ann Thorac Surg 2007; 83 (01) 30-35
• 14 Miró JM, Moreno A, Mestres CA. Infective endocarditis in intravenous drug abusers. Curr Infect Dis Rep 2003; 5 (04) 307-316
• 15 Gansera LS, Eszlari E, Deutsch O, Eichinger WB, Gansera B. High-risk cardiac surgery in patients with intravenous drug abuse and/or active hepatitis C or HIV infection: an ethical discussion of six cases. Thorac Cardiovasc Surg 2016; 64 (01) 2-5
• 16 Cook CC, Rankin JS, Roberts HG. et al. The opioid epidemic and intravenous drug-associated endocarditis: a path forward. J Thorac Cardiovasc Surg 2020; 159 (04) 1273-1278
• 17 Tyerman Z, Shah S, Mehaffey JH. et al. Cost-effectiveness of postoperative drug rehabilitation for injection drug users. Ann Thorac Surg 2020; 110 (02) 492-499
• 18 Mori M, Bin Mahmood SU, Schranz AJ. et al. Risk of reoperative valve surgery for endocarditis associated with drug use. J Thorac Cardiovasc Surg 2020; 159 (04) 1262-1268.e2